PRTN3 and anti-neutrophil cytoplasmic antibody-associated vasculitis: The prevalence of DAH was comparable between the groups of PR3-AAV and MPO-AAV in the Rituximab in ANCA-associated Vasculitis (RAVE) trial (40).